Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D Virus Infection, Including a Randomised, Single Blinded, Placebo-controlled Exploratory Part

NCT06649266 is registered in ClinicalTrials.gov with Ribocure Pharmaceuticals AB as lead sponsor.

NCT NCT06649266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D Virus Infection, Including a Randomised, Single Blinded, Placebo-controlled Exploratory Part
Lead sponsor
Ribocure Pharmaceuticals AB
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 21, 2024
Completion date
August 31, 2027
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d